Abstract: The selection of three key resistance mutations, L90M (protease), K103N and M184V (reverse transcriptase), were measured by allele-specific real-time PCR allowing us to track minority quasispecies with a discriminative power of 0.01-0.2%.
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Discussion: The findings of a ~10-fold reduced viremia in most K65R RT-SHIV infected animals during continued tenofovir monotherapy are reminiscent of observations in people who are infected with M184V mutant HIV-1, and for whom continuation of lamivudine monotherapy is associated with a ~2- to 4-fold reduction in viremia and clinical benefits.
Discussion: This replacement of variants based on replicative capacity would be similar to observations in lamivudine-treated patients, where differences in pre-therapy frequencies of codon 184 mutants also appear to explain the transient detection of M184I mutants, which are then replaced by the more fit M184V mutants.
Synthesis and evaluation of 2'-substituted cyclobutyl nucleosides and nucleotides as potential anti-HIV agents.
Abstract: Whereas the nucleoside analogs were inactive against HIV-1 in culture, the nucleotide showed good activity not only against wild-type and recombinant HIV RT (IC(50)=4.7, 6.9 microM), but also against the M184I and M184V mutants (IC(50)=6.1, 6.9 microM) in cell-free assays.
Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.
PMID: 17436219
2007
The Journal of infectious diseases
Abstract: The fifth infant had the M184V mutation.
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Method: NRTI-selected mutations included T39A, M41L, K43E/Q/N<
Result: The mutations included in this analysis were the 23 positively associated mutations in Table 2 and 11 additional clinically relevant NRTI-resistance mutations (K65R, A62V, T69ins, L74I/V, V75M, Y115F, M184V, and K219R/E/N).
Result: The non-TAM mutations, M184V and L74V, demonstrated no clustering with other NRTI-associated mutations.
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
Abstract: M184V was present in all cases, not followed by further selection of TAMs in a small, unpredictable subgroup of patients.
Abstract: After 54 weeks of treatment with detectable VL, three mutational patterns were observed: Group A (n=4) characterized by M184V without further regimen-associated mutations, group B (n=9) by M184V accompanied by one to three thymidine analogue mutations (TAMs), and group C (n=6) by M184V and four to six TAMs.
Abstract: However, in the majority of patients selection of M184V was associated with accumulation of TAMs at different rates leading to a substantial loss of active NAs, despite continuous virological and immunological benefit when compared with baseline.
Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India.
PMID: 17506605
2007
AIDS research and human retroviruses
Abstract: M184V was the most common observed HIVDR mutation.
Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure.
Abstract: In 7 of 12 children, M184V appeared with one thymidine-analogue-associated mutation (TAM) as the first mutation, while the remaining 5 children had only TAMs appearing either individually (n = 2), or as TAMs 1 (M41L, L210W, and T215Y) and 2 (D67N, K70R, and K219Q/E/R) appearing together (n = 3).
HIV mutation literature information.
PMID: 
2007
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT